General MedicationsINTRAVENOUSStandard
ROMIDEPSIN
ROMIDEPSIN
Standard Dose
10MG/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview ROMIDEPSIN is listed in Drugs@FDA under application 206254 (ANDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient ROMIDEPSIN Form and strength POWDER;INTRAVENOUS - 10MG/VIAL Sponsor FRESENIUS KABI USA Submission history Latest submission status date: 2021-10-12 00:00:00.
Structured Monograph
Clinical summary
Approval overview ROMIDEPSIN is listed in Drugs@FDA under application 206254 (ANDA). Review priority: STANDARD Marketing status: Prescription Active ingredient ROMIDEPSIN Form and strength POWDER;INTRAVENOUS - 10MG/VIAL Sponsor FRESENIUS KABI USA Submission history Latest submission status date: 2021-10-12 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.